Consequently, PRRs have emerged as promising targets for cancer therapy.509 This is particularly evident in the field of cancer immunotherapy, where the agonism of PRRs and their signaling pathways through DNA may act as an adjuvant, stimulating an antitumor response akin to checkpoint inhibition.510 For instance, the activation of NOP2/Sun RNA methyltransferase 2 (NSUN2) maintains global 5-methylcytosine (m5C) RNA methylation, including that of TREX2, stabilizing it and thereby restricting cytosolic dsDNA accumulation and cGAS/STING activation. Here, CGAS is linked to cancer.